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TObjective: Bivalirudin has been successfully used as a replacement for heparin
during on-pump coronary artery bypass grafting. This study was conducted to assess
the effects of the currently suggested protocol for bivalirudin on hemostatic acti-
vation during cardiopulmonary bypass with and without cardiotomy suction.
Methods: Ten patients scheduled for coronary artery bypass grafting were enrolled.
Bivalirudin was given with a bolus of 50 mg in the priming solution and 1.0 mg/kg
for the patient, followed by an infusion of 2.5 mg · kg1 · h1 until 15 minutes
before the conclusion of cardiopulmonary bypass. Cardiopulmonary bypass was
performed with a closed system in 5 patients with and in 5 patients without the use
of cardiotomy suction. Blood samples were obtained before and after cardiopulmo-
nary bypass. D-dimers, fibrinopeptide A, prothrombin 1 and 2 fragments, thrombin-
antithrombin, and factor XIIa were determined.
Results: Values for factor XIIa remained almost unchanged in both groups, indi-
cating a minor effect of contact activation. In patients without cardiotomy suction,
post–cardiopulmonary bypass values for D-dimers, fibrinopeptide A, prothrombin 1
and 2 fragments, and thrombin-antithrombin were not significantly increased com-
pared with pre–cardiopulmonary bypass values. In patients with cardiotomy suc-
tion, values obtained for these parameters had significantly increased compared with
pre–cardiopulmonary bypass values and the values obtained in the group without
cardiotomy suction after cardiopulmonary bypass.
Conclusions: With this protocol, hemostatic activation during cardiopulmonary
bypass was almost completely attenuated when cardiotomy suction was avoided.
Cardiotomy suction results in considerable activation of the coagulation system and
should therefore be restricted and replaced by cell saving whenever possible.
Bivalirudin (Angiomax) is a direct thrombin inhibitor. The pharmacokineticsof bivalirudin are characterized by a short half-life of approximately 25minutes and an elimination that is mainly achieved by proteolytic cleavage
(80%); the remaining 20% is cleared by renal excretion.1 This elimination mecha-
nism, largely independent of particular organ functions, and its short half-life render
bivalirudin an interesting alternative to or replacement for unfractionated heparin
(UFH) for high-dose anticoagulation in percutaneous coronary intervention (PCI)
and cardiovascular surgery. Bivalirudin has been shown to result in favorable
outcomes as compared with UFH in large PCI trials, and it seemed promising during
off-pump coronary artery bypass surgery when used at PCI dosage.2,3 In a recent
pilot investigation involving 20 patients undergoing coronary artery bypass grafting
(CABG), bivalirudin was successfully used for anticoagulation during cardiopul-
monary bypass (CPB).4 The dosing scheme for that investigation was based on prior
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CSPexperiences with the direct thrombin inhibitor r-hirudin and
large pools of pharmacokinetic data derived from PCI stud-
ies.4,5
However, cardiac surgery involving CPB induces acti-
vation of the coagulation/inflammation system caused by
contact of the blood with the large nonendothelial surfaces
of CPB, release and reinfusion of tissue factor–enriched
blood from the operation field aspirated by cardiotomy
suction (CS), surgical trauma, and reperfusion of ischemic
tissue. These procoagulant effects have been shown to occur
with the use of UFH as anticoagulation therapy and even
with the use of coated extracorporeal circuits.6,7 The cur-
rently used bivalirudin scheme for anticoagulation during
CPB has not yet been evaluated with regard to its effect on
hemostatic activation caused by the same factors. This in-
vestigation was performed to evaluate whether the currently
suggested protocol for anticoagulation with bivalirudin dur-
ing CPB provides effective attenuation of hemostatic acti-
vation and to assess the influence of CS in this regard.
Methods
Patients and Anticoagulation Protocol
After approval by the local ethics committee and informed consent
were obtained, 10 patients undergoing elective CABG without
known disturbances of the hemostatic system or previous therapy
with warfarin, aspirin, or clopidogrel for 5 days before surgery
were enrolled in this prospective, randomized investigation. This
pilot investigation was designed to assess a slightly different
dosing protocol than the previous pilot study.4 The bolus for the
pump was 50 mg of bivalirudin, and the bolus for the patient was
bivalirudin 1 mg/kg followed by a constant infusion of 2.5 mg ·
kg1 · h1 until 15 minutes before the conclusion of CPB. Patients
were to receive an additional bolus of bivalirudin only if the ecarin
clotting time decreased to less than 400 seconds. No change was
allowed in the rate of continuous infusion. In all patients, normo-
thermic CPB was performed with a closed non–heparin-coated
CPB system with a collapsible venous reservoir and roller pumps.
Patients were randomized into 2 groups of 5 patients each. In one
group, CS was used in combination with a cell-saving device
(anticoagulation with citrate), whereas in the other group, CS was
TABLE 1. Parameters of hemostatic activation before and
Variable
D-dimers
(g/mL)
TAT
(g/L)
Before CPB
CS 0.4  0.3 3.6 1.2
NCS 1.1 1.0 6.9 3.8
After CPB
CS 3.9  3.7* 126 72*
NCS 1.1 0.9† 7.6 4.2†
CPB, Cardiopulmonary bypass; CS, group with cardiotomy suction; NCS,
fibrinopeptide A; PTF12, prothrombin fragments 1 and 2; FXIIa, factor XIIa
compared with the CS group.clamped out, the heart was passively vented into the venous
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sively with a cell-saving device.
Laboratory Analysis
Blood samples for determination of bivalirudin concentrations and
ecarin clotting time were obtained at 15-minute intervals. Blood
samples for the determination of hemostatic activation were col-
lected 10 minutes after administration of the bivalirudin bolus
(immediately before the start of CPB) and immediately after
termination of CPB. Concentrations of bivalirudin were measured
as described previously.2 D-dimers, fibrinopeptide A, prothrombin
fragments 1 and 2 (PTF12), thrombin-antithrombin (TAT), and
factor XIIa (FXIIa) were determined by standard commercially
available enzyme-linked immunosorbent assay techniques.
Statistical Analysis
Statistical analysis was performed with analysis of variance by
using the Duncan multiple-range test for post hoc analysis.
Results
There were 4 men and 1 woman with a mean age of 55.8 
6.1 years in the CS group and 5 male patients with a mean
age of 66.4  6.3 years (P  .03) in the group without CS.
The mean duration of CPB was 114  12.6 minutes in the
CS group and 94.6  27.8 minutes in the group without CS
(P  .18). Eighty-five data points were obtained for mea-
surement of bivalirudin concentrations during CPB. Of
these, 82 were above the target concentration of 10 g/mL
during CPB. The mean bivalirudin concentrations during
CPB were 13.0 2.5 g/mL (range, 9.5-18.5 g/mL) in the
CS group and 13.3 2.3 g/mL (range, 8.0-17.4 g/mL) in
the group without CS (P  .67). No patient required an
additional bolus of bivalirudin.
The postoperative blood loss was 520  279 mL in the
CS group and 500  281 mL in the group without CS (P 
.93). During the entire course in the hospital, in the CS
group, 4 units of packed red blood cells (median, 0) and 4
units of fresh frozen plasma (median, 0) were transfused. In
the group without CS, 12 units of packed red blood cells
r CPB
FPA
(ng/mL)
PTF12
(nmol/L)
FXIIa
(ng/mL)
5.1 2.1 0.9  0.2 1.4  0.6
6.6 3.7 1.1  0.4 0.8  0.2
130 65* 11.8 7.3* 1.2  0.2
16  10.2† 1.1 0.4† 1.0  0.1
without cardiotomy suction; TAT, thrombin-antithrombin complex; FPA,
nificant difference compared with pre-CPB values. †Significant differenceafte
group
. *Sig(median, 2), 5 units of fresh frozen plasma (median, 0), and
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P1 unit of platelets were transfused. However, most transfu-
sions in the group without CS were given to 1 patient, who
underwent reoperation because of postoperative blood loss
exceeding 1500 mL; bleeding from a sternal artery was
found to be the source of hemorrhage. All patients had an
otherwise uneventful postoperative course and were dis-
charged from the hospital on schedule.
Hemostatic activation data are presented in Table 1.
Regarding the marker of the contact activation system,
FXIIa, no significant changes were observed between pre-
and post-CPB values in the 2 groups. The values for D-
dimers, PTF12, fibrinopeptide A, and TAT as markers for
thrombin and fibrin generation obtained after CPB revealed
only a moderate increase in the patients in the group without
CS as compared with pre-CPB values, whereas the values in
the CS patients were significantly increased as compared
with pre-CPB values and with the values obtained from the
group without CS after CPB.
Discussion
This investigation was performed to assess the effect of the
currently suggested on-pump dosage of bivalirudin on he-
mostatic activation during CPB. According to this protocol,
bivalirudin concentrations were almost exclusively main-
tained above the minimal target concentration of 10 g/mL
during CPB.5 At these concentrations, contact activation by
the nonendothelial surfaces of CPB was almost completely
inhibited, as observed by FXIIa levels that were almost
unchanged after CPB as compared with values obtained
before CPB. Similar to anticoagulation during CPB with
UFH, the observed hemostatic activation seems to be pre-
dominately caused by activation of the tissue factor–related
pathway.6 The fact that hemostatic activation was almost
completely attenuated in the group without CS suggests
that, analogous to UFH, the main source of this tissue
factor–derived hemostatic activation is the blood aspirated
from the operation field.7 When UFH is used, stagnant
blood in the pericardium and pleural space remains antico-
agulated, and thrombin generation is largely attenuated.
Bivalirudin, a compound cleaved by thrombin itself, is a
short-acting anticoagulant and ideally should be adminis-
tered continuously in a “closed circulatory system” with
homogenous distributed blood flow to maintain a consistent
concentration and therapeutic effect. Stagnant blood, partic-
ularly in contact with tissue factor–enriched cavities (eg,
pericardium and plural space), generates large amounts of
thrombin, which may cause thrombus formation in the cav-
ity or may activate the entire coagulation system if it is
aspirated and reperfused into the circulation. This mecha-
nism likely explains the observed marked effect of CS on
systemic hemostatic activation during CPB compared with
data with UFH. TAT was 3.0  0.6 nmol/L without CS
versus 1.5  0.1 nmol/L with CS. Published data from our
The Journal of Thoracicinstitution using a closed system with CS demonstrated
values for TAT of 25.2  21.0 g/L versus 34.6  25.1
g/L, for D-dimers of 1.94  1.74 g/mL versus 2.58 
2.1 g/mL, and for PTF12 of 2.6  1.6 nmol/mL, de-
pending on variations of heparin management.8-10
Despite the marked thrombin generation in the group
with CS, no thrombosis of the CPB circuit or thromboem-
bolic complication of the patients was observed. The fact
that bivalirudin concentrations were maintained at an equiv-
alent level as compared with the group in which CS was
strictly avoided suggests that the larger amounts of throm-
bin generated did not significantly decrease bivalirudin con-
centrations. Therefore, the observed hemostatic activation
may not be associated with CPB thrombosis or thromboem-
bolism, although larger studies are needed to test this
assumption.
This investigation was limited by the small number of
patients involved and the fact that only patients scheduled
for CABG with a closed system were enrolled. However,
even on the basis of this small set of data, our results
provide convincing evidence that, with the current protocol
for bivalirudin, hemostatic activation during CPB is effec-
tively attenuated if CS is strictly avoided. The significant
increases of selected parameters of hemostatic activation
observed in the group with CS strongly suggest that aspi-
ration of blood from the operation field should be avoided
whenever possible and replaced by cell saving if bivalirudin
is used for anticoagulation during CPB. This may limit
indications for this agent if massive reinfusion of blood via
the CS line and storage of large volumes in the cardiotomy
reservoir are anticipated. However, it remains to be demon-
strated how far this problem may be overcome by innova-
tions in perfusion technique.
Further safety studies to assess the use of bivalirudin for
anticoagulation during CPB are warranted. These studies
have to particularly address the effect of CS on patient
outcome. Accordingly, until these safety data have been
compiled, particularly in view of the fact that the use of this
agent for this indication is “off label,” bivalirudin should be
used cautiously for anticoagulation during CPB if extended
use of CS during the procedure is necessary.
We are grateful to Anne Gale, ELS, of the Deutsches Herzzen-
trum Berlin for editorial assistance.
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